This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

A Closer Look at Quest Diagnostics, Lab Corp and Hologic

NEW YORK ( TheStreet) -- Diagnostics providers such as Quest Diagnostics (DGX - Get Report), Lab Corp (LH - Get Report) and Hologic (HOLX - Get Report) have long been sleepy and stable performers. While the Affordable Care Act may not send these stocks rocketing higher, it is likely to give them meaningful boosts to their revenue over the next 12 months.

For every individual diagnosis or treatment, there are often numerous diagnostics that must be run. But in many cases even very simple tests can be out of reach for those without insurance. Obamacare coverage is likely to result in much greater use of diagnostics for as many as 30 million new covered individuals.

However, it remains to be seen how pricing and reimbursements will be affected. Diagnostics providers have been understandably vocal against any changes that will affect pricing and margins, even though there may be a rise in volume that could more than offset declines in pricing.

Of the three diagnostic companies mentioned above, Quest is most likely going to be the safest and most stable long-term winner. At around 11 times earnings, the stock is fairly cheap, but is typically under-appreciated by the analysts.

For the first nine months of the year, the company threw off nearly half a billion dollars in operating cash flow, and it has a 2% dividend yield. Revenue has been fairly constant at around $1.8 billion per quarter, but following the onset of Obamacare, revenue could be due for a moderate increase. Gross margins are around 30% and net margins come in at around 20%, impressive for a company of this size.

In October, the company reported a slight revenue miss, resulting in numerous analyst downgrades. However, the share price has been only minimally affected. One key driver will be the recently launched BRCAdvantage gene sequencing test for hereditary breast and ovarian cancers.

The recent weakness in Quest revenue has made it a somewhat unloved stock for the short term. But this is likely to reverse itself over the next two quarters and the dividend means that investors get paid to wait.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DGX $75.15 -0.03%
HOLX $34.00 1.22%
LH $125.86 0.43%
AAPL $93.64 -0.11%
FB $118.57 0.84%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs